When.com Web Search

  1. Ads

    related to: grail stock

Search results

  1. Results From The WOW.Com Content Network
  2. Grail (company) - Wikipedia

    en.wikipedia.org/wiki/Grail_(company)

    GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. [3] Grail was spun-out from Illumina on June 24, 2024. Their liquid biopsy (also called multi-cancer early ...

  3. Grail's shares fall in Nasdaq debut after spin-off from Illumina

    www.aol.com/news/grails-shares-fall-nasdaq-debut...

    (Reuters) -Shares of Grail fell as much as 13.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina. The stock traded as low as $15.84 after opening at $18. ...

  4. Grail bets big on flagship cancer test after spin-off from ...

    www.aol.com/news/grail-bets-big-flagship-cancer...

    U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial partnerships with health systems ...

  5. Illumina's board approves to spin off Grail in June - AOL

    www.aol.com/news/illuminas-board-approves-spin...

    The gene sequencing machine maker founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market. Illumina's board approves to spin ...

  6. Illumina, Inc. - Wikipedia

    en.wikipedia.org/wiki/Illumina,_Inc.

    Grail uses Illumina sequencing technology for tests. [25] Grail planned to roll out the tests by 2019. [26] In September 2020, Illumina announced a proposed cash and stock deal to acquire Grail for $8 billion. [27] [28] In November 2018, Illumina proposed the acquisition of Pacific Biosciences for $8.00 per share or around $1.2 billion in total.

  7. 10x Genomics - Wikipedia

    en.wikipedia.org/wiki/10x_Genomics

    10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment for use in cellular biology. [3] Prior to starting the company, Saxonov was the founding architect, and director of research and development at 23andMe. [2] Ness left 10x Genomics in December 2016 [4] and in 2018, Justin McAnear ...